Form : Tablets
/ Pack : 10 X 15’s
/ Type : Blister
Description : In this 24-week placebo-controlled study, initial combination treatment of sitagliptin and metformin provided clinically meaningful reductions in HbA1c compared with each monotherapy alone at corresponding dose strengths and compared with the placebo- Journal of Diabetes Investigation 7(5): February 2016.
Form : Tablets
/ Pack : 10 X 10’s
/ Type : Alu Alu
Description : By preventing breakdown of GLP-1 and GIP, Sitagliptin increases the secretion of insulin and suppresses the release of glucagon. As the blood glucose level approaches normal, the amounts of insulin released and glucagon suppressed diminishes, thus tending to prevent an "overshoot" and subsequent hypoglycemia. Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), causes blood glucose to be eliminated through the urine, potently reduce intravascular volume through osmotic diuresis and natriuresis. Impressive results of the landmark SGLT2 inhibitor trials have becoming a powerful adjunctive therapy for the management of people with diabetes and HF- ESC Heart Fail. 2019 Oct; 6(5): 927–935.
Form : Tablets
/ Pack : 10 X 15’s
/ Type : Blister
Description : In this 24-week placebo-controlled study, initial combination treatment of sitagliptin and metformin provided clinically meaningful reductions in HbA1c compared with each monotherapy alone at corresponding dose strengths and compared with the placebo- Journal of Diabetes Investigation 7(5): February 2016.
Form : Tablets
/ Pack : 10 X 15’s
/ Type : Blister
Description : In this 24-week placebo-controlled study, initial combination treatment of sitagliptin and metformin provided clinically meaningful reductions in HbA1c compared with each monotherapy alone at corresponding dose strengths and compared with the placebo- Journal of Diabetes Investigation 7(5): February 2016.
Form : Tablets
/ Pack : 10 X 15’s
/ Type : Alu Alu
Description : By preventing breakdown of GLP-1 and GIP, Sitagliptin increases the secretion of insulin and suppresses the release of glucagon. As the blood glucose level approaches normal, the amounts of insulin released and glucagon suppressed diminishes, thus tending to prevent an "overshoot" and subsequent hypoglycemia. Sitagliptin lowers HbA1c level by about 0.7% points versus placebo.
Composition : Dapagliflozin 10mg + Vildagliptin SR 100mg
Form : Tablets
/ Pack : 10 X 10's
/ Type : ALU ALU
Description : Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), causes blood glucose to be eliminated through the urine, potently reduce intravascular volume through osmotic diuresis and natriuresis. Impressive results of the landmark SGLT2 inhibitor trials have becoming a powerful adjunctive therapy for the management of people with diabetes and HF- ESC Heart Fail. 2019 Oct; 6(5): 927–935.
An interesting observation was made in patients where vildagliptin was combined with insulin. In these patients, an insulin sparing effect was seen, but more interestingly, less hypoglycemia was observed. No direct explanation is available, but further exploration of this phenomenon is warranted because of great clinical importance.- Vasc Health Risk Manag. 2008 Dec; 4(6): 1349-1360.
Form : Mouth Dissolving Tablets
/ Pack : 10 X 10s
/ Type : ALU ALU
Description : Voglibose should be co-administered in conjunction with diet treatment or diet plus oral hypoglycaemic drugs and dose titration must be recommended only if a response is not seen with 0.2 mg tid. The higher dose (0.3 mg three times daily) is effective in decreasing the reaction of VAT( visceral adipose tissue) to SATC (Subcutaneous Adipose Tissue) and glycaemic control was related to changes in VAT but not SATC.For IDDM patients, dose of 0.2 to 0.3 mg tid before meals is administered along with insulin administration - J Clin Diagn Res. 2013 Dec; 7(12): 3023–3027.
Form : Mouth Dissolving Tablets
/ Pack : 10 X 10s
/ Type : ALU ALU
Description : Voglibose should be co-administered in conjunction with diet treatment or diet plus oral hypoglycaemic drugs and dose titration must be recommended only if a response is not seen with 0.2 mg tid. The higher dose (0.3 mg three times daily) is effective in decreasing the reaction of VAT( visceral adipose tissue) to SATC (Subcutaneous Adipose Tissue) and glycaemic control was related to changes in VAT but not SATC.For IDDM patients, dose of 0.2 to 0.3 mg tid before meals is administered along with insulin administration - J Clin Diagn Res. 2013 Dec; 7(12): 3023–3027
Description : In a study of 2741 patients on oral (OAD), there was an inverse relationship between OAD adherence and HbA1c; controlling for baseline HbA1c and therapy regimen, each 10% increase in oral diabetes medication adherence was associated with a 0.1% HbA1c decrease (P = 0.0004), suggesting that adherent patients are more likely to achieve glycemic control than the non-adherent ones - Indian Journal of Endocrinology & metabolism 2015, May June 19 (3) The estimated prevalence of 61.3 million in India is expected to rise to 101.2million (65% increase) by 2030 resulting in every fifth person with diabetes in the world will be an Indian – Ind.J. of Endocrinology & Metabolism-2013 Vol: 17 Iss: 4 P: 594-601.
Description : Dapagliflozin is in a class of drug called SGLT2 inhibitors that works by targeting and helping to stop sodium-glucose transport proteins from allowing glucose that has been filtered out of the blood by the kidneys to be reabsorbed back into the blood.
The SGLT2 proteins are responsible for 90% of the glucose that is reabsorbed into the blood. By inhibiting the SGLT2 proteins. Dapagliflozin allows a significant amount of glucose in the blood to be removed by the kidneys and excreted in the urine.
SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atherosclerotic cardiovascular disease. However, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerotic cardiovascular disease or a history of heart failure - The Lancet, Vol.- 393, Iss.-10166, p31-39.
